The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 study to determine the clinical and pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage II to IV (M0) resectable cutaneous squamous cell carcinoma (Neo-SCC).
 
Maria Gonzalez
No Relationships to Disclose
 
Alexander van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genmab; Menarini Silicon Biosystems; Merck/Pfizer (Inst); MSD Oncology (Inst); NeraCare GmbH; Novartis (Inst); Pierre Fabre (Inst); Provectus Biopharmaceuticals; Sanofi (Inst); Sirius Medical (Inst); Skyline Diagnostics
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Thomas Bennett
No Relationships to Disclose
 
Sydney Ch'ng
No Relationships to Disclose
 
Kerwin Shannon
No Relationships to Disclose
 
Michael Rtshiladze
No Relationships to Disclose
 
Richard Scolyer
Employment - Sydney Local Health District / Royal Prince Alfred Hospital
Leadership - Melanoma Institute Australia
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb GesmbH (Austria); Bristol-Myers Squibb SA (Switzerland); Evaxion Biotech; GlaxoSmithKline; IO Biotech; Merck Sharp & Dohme; metaoptima; MSD Sharp & Dohme (Australia) Pty Limited; Myriad Genetics; NeraCare GmbH; Novartis; Novartis; Novartis; Novartis; Provectus Biopharmaceuticals; QBiotics; Roche; Skyline Diagnostics
Research Funding - Melanoma Research Alliance (MRA); National Health and Medical Research Council; National Health and Medical Research Council; Tour de Cure
Patents, Royalties, Other Intellectual Property - Pending Application (as at 5.9.24): Application number 2024901602, Title: Methods for identifying skin cancer, administering biopsies and treating skin cancer. (Inst)
 
Robert Rawson
Honoraria - MSD
 
Monica Osorio
No Relationships to Disclose
 
Rony Kapoor
No Relationships to Disclose
 
Edward Hsiao
No Relationships to Disclose
 
Helen Rizos
No Relationships to Disclose
 
Serigne Lo
Consulting or Advisory Role - Skyline Diagnostics
 
Alexander Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Angela Hong
No Relationships to Disclose
 
Georgina Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; GI Innovation Inc; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron; Scancell LImited; Skyline Diagnostics
 
Ines Esteves Domingues Pires da Silva
Honoraria - MSD
Consulting or Advisory Role - MSD; Regeneron; Strand Therapeutics